Les Laboratoires Servier

Vernalis &r&d) Ltd.

Merrell Dow Pharmaceuticals

Merrell Pharmaceuticals, Inc.

Merrell Toraude Et Compagnie

Les Laboratories Servier

Adir Et Compagnie

Merrell Toruade Et Compagnie

Vernalis Limited

Patrick Casara

Thierry Le Diguarher

Guillaume De Nanteuil

Arnaud Le Tiran

Olivier Geneste

James Brooke Murray

I-Jen Chen

James Edward Paul Davidson

Jean-Michel Henlin

Christopher John Graham

Pierre Lestage

John Hickman

Jérôme-Benoît Starck

Alain Dhainaut

Miklós Nyerges

Gordon Tucker

Stéphane Depil

Anne-Marie Chollet

Alain Pierre

Michel Jung

Ghanem Atassi

Brian W Metcalf

Charles Danzin

Simon Bedford

Serge Halazy

Brian Lockhart

Nicolas Guilbaud

Claire Walmsley

Stuart Christopher Ray

Gilbert Dorey

Fany Panayi

Daniel Maddox

Jean-Francedillaois Nave

Jerome-Benoit Starck

Jacqueline Bonnet

Françoise Perron-Sierra

Massimo Sabatini

Lionel Bert

Anne Marie Chollet

Dominique Saint-Dizier

Anita Roger

Jéröme-Benoit Starck

Jean-Francoise Nave

Stuart Ray

Miklos Nyerges

Stephane Depil

Compounds of formula (I): wherein R, R, R, R, R, R, R, A, A, T and W are as defined in the description. Medicinal products containing the same which are useful in treating conditions requiring a pro-apoptotic agent.

Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them

Compounds of formula (I): wherein R, R, R, R, R, R, R, R, R, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them

Compounds of formula (I): wherein R, R, R, R, R, R, R, A, A, T and W are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Compounds of formula (I): wherein:  Medicinal products containing the same which are useful in the treatment of conditions associated with central histaminergic systems.

Azabicyclo[3.2.0] hept-3-yl compounds, a process for their preparation and pharmaceutical compositions containing them

Compounds of formula (I): wherein:  Medicinal products containing the same which are useful in the treatment of cognitive and psycho-behavioural disorders associated with cerebral ageing, with neurodegenerative diseases or with cranial traumas and also in the treatment of mood disorders, of schizophrenia and of cognitive disorders associated therewith, of sleep disorders, of sleep-waking rhythm disorders, of attention-deficit hyperactivity syndrome or of obesity.

Azabicylic compounds, a process for their preparation and pharmaceutical compositions containing them

A compound selected from those of formula (I): wherein Medicinal products containing the same which are useful for treating conditions associated with central histaminergic systems.

Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them

Vitronectin receptor antagonist bicyclic compounds, preparation method and compositions containing same

Cycloheptene compounds

The invention concerns a compound of formula (I) wherein: n is equal to 0 or 1; R , R , R , R represent a hydrogen or an alkyl group, or R and R together form a cycloalkyl group; R represents a hydrogen, an alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, hetereoalkylalkyl, hetereocycloalkyl, hetereocycloalkylalkyl group (all optionally substituted), or a &mdash;CO&mdash;R group; and R represents R or OR or NR R , with R representing an aryl, arylalkyl, heteroaryl or heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl group (all optionally substituted), and R representing an alkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl (all optionally substituted); or R and R form with the nitrogen atom and the Z group bearing them a saturated monocyclic, bicyclic or tricyclic group, partially unsaturated or unsaturated, with 5 to 16 chain links containing 1 to 7 heteroatoms and optionally substituted; R represents a hydrogen atom or a hydroxy group, and in the latter case R , R , R , R are independently selected among hydrogen and alkyl; Z represents a hydroxy, alkoxy, alkenyloxy, benzyloxy group or a NH&mdash;OR group; X represents a sulphur, a SO, SO group (in those cases where R and R are different from an alkyl) or a group &mdash;CO&mdash;O&mdash; (in which case R and R form a cycloalkyl group), or X represents an oxygen atom; W represents a W &mdash;(A) or W &mdash;B&mdash;W &mdash;(A) group wherein W and W represent an aryl or heteroaryl group, A is a standard substituent of aromatic cycles, B a bond, an oxygen or an alkylene, alkenylene, alkynylene group, and p is an integer ranging between 0 and 5; T and T represent a bond or an alkylene, alkenylene, or alkynylene group. The invention is useful for preparing medicines.

Carboxylic and hydroxamic acid compounds inhibiting metalloproteases, method for preparing same and pharmaceutical compositions containing them

Dihydro- and tetrahydro-quinoline compounds

Disclosed are novel unsaturated phosphonate derivatives of certain purines or pyrimidines useful as antiviral agents, methods useful for their preparation and use of these compounds as antiviral agents effective against DNA viruses, retroviruses and viruses involved in tumor formation.

Ethylenic and allenic phosphonate derivatives of purines

Unsaturated acetylene phosphonate derivatives of purines

This invention relates to a novel synthesis of 4-amino-5-hexenoic acid by thermal rearrangements, and to the novel intermediates produced thereby.

Ethyl 6-formyloxy-4-hexenoate

Growing community of inventors

Villennes sur Seine, France

Patrick Casara